Article history: Received: 2018 Background and Aims: Cervical cancer is the second most common cancer in women worldwide. The presence of HPV has been implicated in more than 99% of cervical cancer worldwide. Human papillomavirus is a heterogeneous virus, categorized to two groups of highrisk and low-risk genotyped according to the level of infection that leads to cervical cancer. HPV screening is recommended for the further evaluation of abnormal pap test or during follow-up after treating precancerous lesions. Genotyping of different high-risk HPV (hrHPV) types obtained from smear tests has not yet gained widespread acceptance in clinical practice. Genotyping of hrHPV could be helpful for the risk stratification of HPV-positive.

